The cardiovascular community, expecting the usual incremental class effect, instead got the SELECT trial, a 20% reduction in major adverse cardiovascular events in patients with overweight or obesity and established cardiovascular disease, in patients without diabetes
Obese and overweight individuals with metabolically-related health conditions who are already taking a receptor agonists find that they are consuming far less food because they feel full sooner and longer, it means that every bite counts even more for getting the nutrition needed for proper signaling of neurotransmitters
The wound is closed in three layers (mucosa, muscle, skin) to restore lip continuity
When administered under medical supervision, Semaglutide is safe and effective for weight loss
As early GLP-1 therapies move through their patent lifecycle, pharmaceutical companies face the familiar challenge of maintaining value in the face of eventual generic competition
But its not expected to get FDA approval until 2027, she said